Genetic testing for pathogenic variants in BRCA1 and BRCA2 is widely available in breast and ovarian cancer, to enable not only early detection and risk reduction, but also to guide cancer treatment, e.g. consideration of the use of olaparib in chemotherapy regimens [4]. This evidence concerns the gene BRCA2 and ovarian cancer.